Stock ARQT ARCUTIS BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Arcutis Biotherapeutics, Inc.

Equities

ARQT

US03969K1088

Real-time Estimate Cboe BZX
Other stock markets
 20:32:57 14/05/2024 BST 		5-day change 1st Jan Change
8.085 USD +1.19% Intraday chart for Arcutis Biotherapeutics, Inc. +2.79% +150.77%
04-10 Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes CI
03-18 Arcutis Biotherapeutics, Inc.(NasdaqGS:ARQT) added to S&P Biotechnology Select Industry Index CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
GL
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
GL
Arcutis Appoints David Topper as Chief Financial Officer
GL
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
AQ
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
AQ
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
GL
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
AQ
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
GL
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
AQ
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
GL
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
GL
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
GL
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
AQ
Arcutis Biotherapeutics to Present at the TD Cowen 44th Annual Health Care Conference
AQ
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARQT Stock
  4. News Arcutis Biotherapeutics, Inc.
  5. Press Releases